Obesity is described by many as the epidemic of the 21st century. Currently, limited and suboptimal drugs are available to the clinician’s therapeutic armamentarium. However, novel agents and combination schemes, mainly with Incretin Analogs, seem to be revolutionizing the way we will soon be treating overweight and obesity. In this podcast, we discuss notable drug advancements and concepts of novel agents, the need for metabolism clinics for the interaction of various medical specialties, and bariatric/metabolic surgery in managing individuals with chronic metabolic conditions.

There is more to come; please stay tuned!

The authors own the copyright to all the contents of this Podcast. All rights reserved. Users of this Podcast may save and use the information contained in the Podcast only for personal or other non-commercial purposes. No other use, including, but not limited to, educational, reproduction, retransmission or editing, of this Podcast may be made without the prior written permission of the authors. Permission may be requested by contacting the authors via email. Disclaimer: The information, statements, opinions and/or recommendations presented are solely those of the authors and are offered for general education only; any reliance on or use of the information provided in this Podcast is done at the listener's discretion and risk. This Podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. If you are not a medical doctor, please always seek the advice of your physician or other qualified licensed health care provider regarding any decision or action related to any medical condition or treatment and before undertaking a new therapy; never disregard professional medical advice or delay in seeking it due to information you have heard in this Podcast. The authors assume no responsibility or liability for the accuracy or completeness of the content contained herein and/or in any third-party materials. Finally, authors make no warranty that this Podcast, or the server that makes it available, is free of viruses, worms, or other elements or codes that may have contaminating or destructive properties. Authors expressly disclaim any and all liability or responsibility for any direct, indirect, incidental, special, consequential, or other damages arising out of any individual's use of, reference to, reliance on, or inability to use this podcast or the information presented in this podcast.

Este episodio es la traducción en español de nuestra conversación con el Dr. Christos Mantzoros, profesor y endocrinólogo de la Facultad de Medicina de Harvard, sobre el cambio de la terminología de Hígado Graso No Alcohólico (NAFLD por sus siglas en íngles) hacia la Enfermedad Hepática Esteatósica Asociada a Disfunción Metabólica (MASLD). Además hablaremos de la importancia de esta nueva nomenclatura y sus implicaciones en la clínica y la investigación.

El consenso que guió el cambio, hacia a una terminología más precisa y apropiada, está respaldado por los avances en la comprensión de la fisiopatología multisistémica y multifactorial MASLD.

¡Únete a nosotros para aprender más!

¡Hay más por venir!

¡Sigan conectados!

The authors own the copyright to all the contents of this Podcast. All rights reserved. Users of this Podcast may save and use the information contained in the Podcast only for personal or other non-commercial purposes. No other use, including, but not limited to, educational, reproduction, retransmission or editing, of this Podcast may be made without the prior written permission of the authors. Permission may be requested by contacting the authors via email. Disclaimer: The information, statements, opinions and/or recommendations presented are solely those of the authors and are offered for general education only; any reliance on or use of the information provided in this Podcast is done at the listener's discretion and risk. This Podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. If you are not a medical doctor, please always seek the advice of your physician or other qualified licensed health care provider regarding any decision or action related to any medical condition or treatment and before undertaking a new therapy; never disregard professional medical advice or delay in seeking it due to information you have heard in this Podcast. The authors assume no responsibility or liability for the accuracy or completeness of the content contained herein and/or in any third-party materials. Finally, authors make no warranty that this Podcast, or the server that makes it available, is free of viruses, worms, or other elements or codes that may have contaminating or destructive properties. Authors expressly disclaim any and all liability or responsibility for any direct, indirect, incidental, special, consequential, or other damages arising out of any individual's use of, reference to, reliance on, or inability to use this podcast or the information presented in this podcast.

In this episode, Dr. Christos Mantzoros, Professor and Endocrinologist at Harvard Medical School and the editor-in-chief of the Journal Metabolism: Clinical and Experimental, will guide the discussion about the ongoing journey towards refining the NAFLD terminology to Steatotic Liver Disease (SLD) and will shed light to the significance of the recent nomenclature change.

The consensus to shift to a new, more accurate, and appropriate name is underpinned by the advances in understanding the multisystem and multifactorial pathophysiology of metabolic dysfunction-associated steatotic liver disease (MASLD).

Join us to learn more!

There is more to come!

Please stay tuned!

The authors own the copyright to all the contents of this Podcast. All rights reserved. Users of this Podcast may save and use the information contained in the Podcast only for personal or other non-commercial purposes. No other use, including, but not limited to, educational, reproduction, retransmission or editing, of this Podcast may be made without the prior written permission of the authors. Permission may be requested by contacting the authors via email. Disclaimer: The information, statements, opinions and/or recommendations presented are solely those of the authors and are offered for general education only; any reliance on or use of the information provided in this Podcast is done at the listener's discretion and risk. This Podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. If you are not a medical doctor, please always seek the advice of your physician or other qualified licensed health care provider regarding any decision or action related to any medical condition or treatment and before undertaking a new therapy; never disregard professional medical advice or delay in seeking it due to information you have heard in this Podcast. The authors assume no responsibility or liability for the accuracy or completeness of the content contained herein and/or in any third-party materials. Finally, authors make no warranty that this Podcast, or the server that makes it available, is free of viruses, worms, or other elements or codes that may have contaminating or destructive properties. Authors expressly disclaim any and all liability or responsibility for any direct, indirect, incidental, special, consequential, or other damages arising out of any individual's use of, reference to, reliance on, or inability to use this podcast or the information presented in this podcast.

La obesidad es la epidemia del siglo XXI, pero ¿qué es y por qué la desarrollamos?
 
¿Es una enfermedad? ¿Existe la obesidad metabólicamente saludable y la no saludable?
 
¡Bienvenido a la serie sobre la obesidad! En este primer episodio, presentaremos conceptos críticos sobre cómo desarrollamos la obesidad y por qué es importante.
 
¡Estén atentos de nuestros siguientes episodios de obesidad!

 
Los autores poseen los derechos de autor de todos los contenidos de este Podcast. Reservados todos los derechos. Los usuarios de este Podcast pueden guardar y usar la información contenida en el Podcast solo para fines personales o no comerciales. No se puede hacer ningún otro uso, incluidos, entre otros, educativos, de reproducción, retransmisión o edición, de este Podcast sin el permiso previo por escrito de los autores. Se puede solicitar permiso comunicándose con los autores por correo electrónico a lvalenz1@bidmc.harvard.edu.
 
Descargo de responsabilidad:
La información, declaraciones, opiniones y/o recomendaciones presentadas son únicamente de los autores y se ofrecen únicamente para educación general; cualquier dependencia o uso de la información proporcionada en este Podcast se realiza a discreción y riesgo del oyente. Este Podcast no pretende ser un sustituto del consejo, diagnóstico o tratamiento médico profesional. Si no es médico, busque siempre el consejo de su médico u otro proveedor de atención médica autorizado y calificado con respecto a cualquier decisión o acción relacionada con cualquier condición médica o tratamiento y antes de emprender una nueva terapia; nunca ignore el consejo médico profesional ni se demore en buscarlo debido a la información que ha escuchado en este Podcast. Los autores no asumen ninguna responsabilidad u obligación por la exactitud o integridad del contenido incluido aquí y/o en cualquier material de terceros. Finalmente, los autores no garantizan que este Podcast, o el servidor que lo pone a disposición, esté libre de virus, gusanos u otros elementos o códigos que puedan tener propiedades contaminantes o destructivas.
 
Los autores renuncian expresamente a cualquier y toda responsabilidad por cualquier daño directo, indirecto, incidental, especial, consecuente o de otro tipo que surja del uso, la referencia, la confianza o la incapacidad de cualquier persona para usar este podcast o la información presentada en este podcast.

La enfermedad del hígado graso no alcohólico (NAFLD, por sus siglas en inglés) es una importante epidemia de salud pública estrechamente relacionada con las epidemias de obesidad y síndrome metabólico. Su prevalencia, combinada con los avances recientes de la investigación, requiere que los endocrinólogos y los médicos de atención primaria participen en la identificación y el manejo de las personas afectadas o en riesgo de desarrollar esta enfermedad.

Bienvenidos a nuestro episodio "Enfermedad del hígado graso: una necesidad clínica no satisfecha";

Hay más por venir en nuestro podcast, ¡estén atentos!

The authors own the copyright to all the contents of this Podcast. All rights reserved. Users of this Podcast may save and use the information contained in the Podcast only for personal or other non-commercial purposes. No other use, including, but not limited to, educational, reproduction, retransmission or editing, of this Podcast may be made without the prior written permission of the authors. Permission may be requested by contacting the authors via email. Disclaimer: The information, statements, opinions and/or recommendations presented are solely those of the authors and are offered for general education only; any reliance on or use of the information provided in this Podcast is done at the listener's discretion and risk. This Podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. If you are not a medical doctor, please always seek the advice of your physician or other qualified licensed health care provider regarding any decision or action related to any medical condition or treatment and before undertaking a new therapy; never disregard professional medical advice or delay in seeking it due to information you have heard in this Podcast. The authors assume no responsibility or liability for the accuracy or completeness of the content contained herein and/or in any third-party materials. Finally, authors make no warranty that this Podcast, or the server that makes it available, is free of viruses, worms, or other elements or codes that may have contaminating or destructive properties. Authors expressly disclaim any and all liability or responsibility for any direct, indirect, incidental, special, consequential, or other damages arising out of any individual's use of, reference to, reliance on, or inability to use this podcast or the information presented in this podcast.

Nonalcoholic fatty liver disease (NAFLD) is a major public health epidemic closely linked to the epidemics of obesity and the metabolic syndrome. Its prevalence, combined with recent research advances, necessitates that endocrinologists and primary care physicians are involved in identifying and managing persons affected by, or at risk for developing this disease.

Welcome to our episode Fatty Liver Disease: An Unmet Clinical Need;

There is more to come, please stay tuned!

The authors own the copyright to all the contents of this Podcast. All rights reserved. Users of this Podcast may save and use the information contained in the Podcast only for personal or other non-commercial purposes. No other use, including, but not limited to, educational, reproduction, retransmission or editing, of this Podcast may be made without the prior written permission of the authors. Permission may be requested by contacting the authors via email at lvalenz1@bidmc.harvard.edu.

Disclaimer:

The information, statements, opinions and/or recommendations presented are solely those of the authors and are offered for general education only; any reliance on or use of the information provided in this Podcast is done at the listener's discretion and risk. This Podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. If you are not a medical doctor, please always seek the advice of your physician or other qualified licensed health care provider regarding any decision or action related to any medical condition or treatment and before undertaking a new therapy; never disregard professional medical advice or delay in seeking it due to information you have heard in this Podcast. The authors assume no responsibility or liability for the accuracy or completeness of the content contained herein and/or in any third-party materials. Finally, authors make no warranty that this Podcast, or the server that makes it available, is free of viruses, worms, or other elements or codes that may have contaminating or destructive properties. 

Authors expressly disclaim any and all liability or responsibility for any direct, indirect, incidental, special, consequential, or other damages arising out of any individual's use of, reference to, reliance on, or inability to use this podcast or the information presented in this podcast.

Bienvenidos al primer episodio de nuestro podcast  ¡Estamos muy emocionados de que te unas a nosotros!

Gracias por estar acá,

El Mantzoros Lab,

¡Apasionados por la Endocrinología, la Innovación y la Mentoría!